Short Interest in uniQure NV (QURE) Expands By 29.7%
uniQure NV (NASDAQ:QURE) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,158,664 shares, a growth of 29.7% from the August 31st total of 893,398 shares. Based on an average daily volume of 175,000 shares, the short-interest ratio is currently 6.6 days. Currently, 8.5% of the shares of the stock are short sold.
Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in uniQure NV by 95.6% in the first quarter. Renaissance Technologies LLC now owns 205,800 shares of the company’s stock worth $2,445,000 after buying an additional 100,600 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in uniQure NV by 5.8% in the first quarter. UBS Asset Management Americas Inc. now owns 345,403 shares of the company’s stock worth $4,103,000 after buying an additional 18,803 shares in the last quarter. Acadian Asset Management LLC bought a new stake in uniQure NV during the second quarter worth approximately $804,000. Fox Run Management L.L.C. bought a new stake in uniQure NV during the second quarter worth approximately $122,000. Finally, Acrospire Investment Management LLC boosted its stake in uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock worth $127,000 after buying an additional 13,498 shares in the last quarter. 32.38% of the stock is owned by institutional investors and hedge funds.
Shares of uniQure NV (NASDAQ:QURE) opened at 7.65 on Wednesday. The company has a 50-day moving average of $8.08 and a 200-day moving average of $10.03. The stock’s market capitalization is $192.24 million. uniQure NV has a 52-week low of $6.68 and a 52-week high of $22.79.
uniQure NV (NASDAQ:QURE) last released its earnings results on Thursday, August 25th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.02. uniQure NV had a negative net margin of 537.62% and a negative return on equity of 61.96%. Equities research analysts anticipate that uniQure NV will post ($3.71) EPS for the current year.
Several research analysts have commented on the stock. Leerink Swann reissued a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. HC Wainwright began coverage on shares of uniQure NV in a report on Thursday, August 4th. They set a “buy” rating and a $21.00 price objective for the company. Chardan Capital set a $35.00 price target on shares of uniQure NV and gave the company a “buy” rating in a report on Thursday, July 28th. Jefferies Group set a $28.00 price target on shares of uniQure NV and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, Zacks Investment Research downgraded shares of uniQure NV from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $28.10.
About uniQure NV
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.